Hepatitis Therapeutics Market Expected to Reach $19.7 Billion by 2030

According to a new report published by Allied Market Research, titled, “Hepatitis Therapeutics Market by Diseases Type, Drug Class, and Distribution Channel: global opportunity analysis and industry forecast, 2021–2030," the global hepatitis therapeutics market size was valued at $14,479.64 Million in 2020, and is projected to reach $19,715.74 Million by 2030, registering a CAGR of 3.1% from 2021 to 2030.

Hepatitis is inflammation of the liver. Inflammation of liver is swelling that happens when tissues of the body are injured or infected by any pathogen. The swelling of the liver can damage and affect the liver functions for long term. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. The five main viral classifications of hepatitis are hepatitis A, B, C, D, E and G. Further, other variants of hepatitis include autoimmune hepatitis and hepatitis that occurs as a secondary result of medications, drugs, toxins, and alcohol.

Rise in prevalence of hepatitis and its other variants, product approvals and launches are the major factors that boost the growth of the hepatitis therapeutics market. In addition, rise in number of product approvals, are other factors that further drive the growth of the market. However, high cost of the therapy is expected to restrain the growth of the hepatitis therapeutics market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period owing to increase in opportunities in untapped markets due to availability of improved healthcare industry infrastructure.

The hepatitis therapeutics market is segmented on the basis of disease type, drug class, distribution channel, and region.

On the basis of disease type, the market is categorized into hepatitis B, hepatitis C and Others (hepatitis A, D, E and G). The hepatitis C segment dominated the global hepatitis therapeutics market in 2020, and is anticipated to continue this trend during the forecast period. Key factors, such as higher prevalence of hepatitis C, and increase in number of product approvals, drive the growth of the market. In addition, increasing clinical trials for development of new drugs for other type of hepatitis (A, D, E and G), and increase in usage of hepatitis therapeutics will further drive the growth of the market.

By drug class, the market is divided into oral antivirals, and immune modulators. The oral antivirals segment is anticipated to depict significant growth during the forecast period due to rising product approvals from government regulatory authorities such as USFDA, EMA and product launches by major players.

By distribution channel, the market is bifurcated into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is anticipated to depict largest growth during the forecast period due to increasing drug availability of both branded and generics. In addition, online providers are expected to show fastest growth owing to the lucrative discount offers provided by the online providers which is going to attract more customers to opt for online provider’s services.

By region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA. North America is expected to collect the largest share in the market owing to the huge number of patient population in the U.S. Further, Asia-Pacific is anticipated to exhibit fastest growing segment owing to the increasing drug approvals and drug launches of hepatitis therapeutics in the Asian countries such as India, China, and Japan.

Key Findings Of The Study

• Based on disease type, the hepatitis C segment held the largest share in the global hepatitis therapeutics market in 2020.
• On the basis of drug class, the oral antivirals segment held the largest market share in 2020 and is expected to remain dominant throughout the forecast period.
• On the basis of distribution channel, the drug stores and retail pharmacies held largest market share in 2020 and is expected to remain dominant throughout the forecast period.
• Based on region, North America is expected to experience growth at the highest rate, registering a CAGR of 41.16% during the forecast period.

Asia-Pacific is projected to account for a fastest growth of the global hepatitis therapeutics market with CAGR of 4.3% during the forecast period. The market in the region is anticipated to grow in the future, owing to rise in prevalence of acute and chronic hepatitis, increase in approvals and launching of new hepatitis drugs, and rise in patient awareness toward applications of hepatitis therapeutics in the region